Xeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million. Shannon said the product recorded highs in referrals, new patient starts, patients on therapy, new prescribers and total prescribers. On June 11, Xeris received a notice of allowance from the U.S. Patent Office for a new KEVEYIS patent. About Xeris Biopharma (NASDAQ:XERS)Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases.